• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Elicio Therapeutics Inc (NQ: ELTX )

    4.530 -0.160 (-3.41%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 24, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 46,672
    Open 4.640
    Bid (Size) 3.870 (2)
    Ask (Size) 5.250 (5)
    Prev. Close 4.690
    Today's Range 4.330 - 4.779
    52wk Range 2.960 - 11.45
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Why Is Cancer Vaccine Developer Elicio Therapeutics Stock Trading Lower On Friday?
    Elicio Therapeutics announced promising preliminary data from the AMPLIFY-7P Phase 1a study of ELI-002 7P, showing extended median disease-free survival in patients with mKRAS-driven solid tumors. 
    Via Benzinga
    Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering
    From Elicio Therapeutics Inc.
    Via GlobeNewswire

    Performance

    YTD
    -23.61%
    -23.61%
    1 Month
    -36.55%
    -36.55%
    3 Month
    -50.87%
    -50.87%
    6 Month
    +21.12%
    +21.12%
    1 Year
    -54.33%
    -54.33%

    More News

    Read More
    Why Is Elicio Therapeutics (ELTX) Stock Down 36% Today?
    Via InvestorPlace
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
    Via InvestorPlace
    First Patient Dosed In Phase 2 Study Of Elicio Therapeutics’ ELI-002 7P
    Via News Direct
    Elicio Therapeutics Announces Proposed Public Offering
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    Elicio Therapeutics Unveils Promising Phase 1a Data For ELI-002 7P In mKRAS Tumors
    Via News Direct
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    ELTX Stock Earnings: Elicio Therapeutics Beats EPS for Q1 2024
    Via InvestorPlace
    Elicio Therapeutics (NASDAQ: ELTX) Makes Strides In Growing Cancer Vaccination Industry
    Via News Direct
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    Unlocking the Power of Immunotherapy: Elicio Therapeutics’ (NASDAQ: ELTX) Novel AMP Platform
    Via News Direct
    Topics Death
    Exposures Death
    ELTX Stock Earnings: Elicio Therapeutics Misses EPS for Q4 2023
    Via InvestorPlace
    Benzinga's 2024 Virtual Healthcare: What's Next In Health?
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating Power Of Amphiphile-Immunotherapy
    Via News Direct
    Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
    From Elicio Therapeutics Inc.
    Via GlobeNewswire
    Elicio Therapeutics Announces Publication Of Preclinical Data Demonstrating Power Of Amphiphile-Immunotherapy
    Via Benzinga
    First Patient Dosed In Phase 2 Study Of Elicio Therapeutics' ELI-002 7P
    Via Benzinga
    Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutics' AMPLIFY-201 Phase 1 Solid Tumor Study Of ELI-002
    Via News Direct
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.